ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 380,74
0,92%
Dow Jones
42 575,65
0,00%
DAX
19 909,14
-0,25%
Brent Oil
74,565
0,63%
Bitcoin
95 143,53
2,68%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Spyre Therapeutics Inc (SYRE) Cours

Spyre Therapeutics Inc

Spyre Therapeutics Inc (SYRE)

NASDAQ
23,015
0,475
( 2,11% )
Mis à jour : 16:49:34
Retardé de 15 minutes

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Statistiques et détails clés

Dernier
23,015
Prix Achat
22,94
Prix Vente
23,10
Volume échangé
41 364
22,64 Fourchette du Jour 24,05
18,54 Plage de 52 semaines 47,97
Cap du marché
1,184B
Clôture Veille
22,54
Ouverture
22,85
Dernière Transaction
1
@
23.0108
Dernière heure de transaction
16:49:36
Volume financier
US$ 960 094
VWAP
23,2109
Volume moyen (3 m)
538 007
Actions en circulation
51 431 220
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-1,82
Bénéfice par action (BPA)
-6,59
Chiffre d'affairess
886k
Bénéfice net
-338,79M

À propos de Spyre Therapeutics Inc

Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an e... Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an early clinical development stage. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.spyre.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Spyre Therapeutics Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker SYRE. Le dernier cours de clôture d'Spyre Therapeutics était de US$22,54. Au cours de la dernière année, les actions de Spyre Therapeutics ont été négociées dans une fourchette de prix de US$ 18,54 à US$ 47,97.

Spyre Therapeutics compte actuellement 51 431 220 actions en circulation. La capitalisation boursière d'Spyre Therapeutics est de US$1,16 milliard. Spyre Therapeutics a un ratio cours/bénéfice (ratio PE) de -1.82.

SYRE Dernières nouvelles

Plus de nouvelles

Spyre Therapeutics Added to the Nasdaq Biotechnology Index

Spyre Therapeutics Added to the Nasdaq Biotechnology Index PR Newswire WALTHAM, Mass., Dec. 18, 2024 WALTHAM, Mass., Dec. 18, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a...

18 Décembre 2024
PR Newswire (US)

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Announces Grants of Inducement Awards PR Newswire WALTHAM, Mass., Dec. 2, 2024 WALTHAM, Mass., Dec. 2, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the...

02 Décembre 2024
PR Newswire (US)

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies PR Newswire WALTHAM, Mass., Dec. 2, 2024 Spyre is concurrently advancing...

02 Décembre 2024
PR Newswire (US)

Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference PR Newswire WALTHAM, Mass., Nov. 25, 2024 WALTHAM, Mass., Nov. 25, 2024 /PRNewswire/ -- Spyre Therapeutics...

25 Novembre 2024
PR Newswire (US)

Form 8-K - Current report

19 Novembre 2024
Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]

19 Novembre 2024
Edgar (US Regulatory)

Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock

Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock PR Newswire WALTHAM, Mass., Nov. 18, 2024 WALTHAM, Mass., Nov. 18, 2024 /PRNewswire/ -- Spyre Therapeutics...

19 Novembre 2024
PR Newswire (US)

Form 424B5 - Prospectus [Rule 424(b)(5)]

18 Novembre 2024
Edgar (US Regulatory)

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants PR Newswire WALTHAM, Mass., Nov. 18, 2024 WALTHAM, Mass., Nov. 18, 2024 /PRNewswire/ -- Spyre...

18 Novembre 2024
PR Newswire (US)

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]

18 Novembre 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.565-2.3960983884623.5824.3422.3729697823.36093136CS
4-4.565-16.551849166127.5829.0622.3748700924.85423532CS
12-4.485-16.309090909127.540.122.3753800729.25728092CS
26-0.695-2.9312526360223.7140.122.3751973828.6298395CS
521.0254.6612096407521.9947.9718.5452257329.58874926CS
15612.205112.90471785410.8147.9710.4249111029.29201321CS
26012.205112.90471785410.8147.9710.4249111029.29201321CS

SYRE - Frequently Asked Questions (FAQ)

What is the current Spyre Therapeutics share price?
The current share price of Spyre Therapeutics is US$ 23,015
How many Spyre Therapeutics shares are in issue?
Spyre Therapeutics has 51 431 220 shares in issue
What is the market cap of Spyre Therapeutics?
The market capitalisation of Spyre Therapeutics is USD 1,16B
What is the 1 year trading range for Spyre Therapeutics share price?
Spyre Therapeutics has traded in the range of US$ 18,54 to US$ 47,97 during the past year
What is the PE ratio of Spyre Therapeutics?
The price to earnings ratio of Spyre Therapeutics is -1,82
What is the cash to sales ratio of Spyre Therapeutics?
The cash to sales ratio of Spyre Therapeutics is 698,26
What is the reporting currency for Spyre Therapeutics?
Spyre Therapeutics reports financial results in USD
What is the latest annual turnover for Spyre Therapeutics?
The latest annual turnover of Spyre Therapeutics is USD 886k
What is the latest annual profit for Spyre Therapeutics?
The latest annual profit of Spyre Therapeutics is USD -338,79M
What is the registered address of Spyre Therapeutics?
The registered address for Spyre Therapeutics is 1521 CONCORD PIKE, SUITE 201, NEW CASTLE, WILMINGTON, DELAWARE, 19803
What is the Spyre Therapeutics website address?
The website address for Spyre Therapeutics is www.spyre.com
Which industry sector does Spyre Therapeutics operate in?
Spyre Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
APMAptorum Group Ltd
US$ 5,8565
(332,21%)
63,68M
ONCOOnconetix Inc
US$ 1,8809
(330,41%)
178,68M
BDMDBaird Medical Investment Holdings Ltd
US$ 4,035
(284,29%)
8,18M
VRMEVerifyMe Inc
US$ 1,825
(131,04%)
76,68M
FLYEFly E Group Inc
US$ 1,195
(78,36%)
43,47M
SGMOSangamo Therapeutics Inc
US$ 1,0925
(-53,31%)
17,08M
WATTEnergous Corporation
US$ 1,435
(-45,85%)
16,35M
COCPCocrystal Pharma Inc
US$ 2,035
(-37,38%)
294,87k
HUBCWHub Cyber Security Ltd
US$ 0,035
(-36,36%)
218,55k
SHOTWSafety Shot Inc
US$ 0,10
(-33,38%)
499
SVMHSRIVARU Holding Ltd
US$ 0,0524
(56,89%)
489,71M
EYENEyenovia Inc
US$ 0,1579
(39,36%)
277,5M
CRKNCrown Electrokinetics Corporation
US$ 0,1714
(23,58%)
255,06M
XTIAXTI Aerospace Inc
US$ 0,0422
(6,84%)
238,94M
ONCOOnconetix Inc
US$ 1,8809
(330,41%)
178,68M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
SYRE
Spyre Therapeutics
BIT
S32577
Societe Generale Effekten
EU
FR001400LKN8
SG Issuer Sg Issuer Zc J...
DOWI
DWCINB
DJ US Insurance Brokers ...
BIT
S5LNIO
Societe Generale Effekten
LSE
0QFY
Tarczynski
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés